Antibody suppresses HIV for four monthsA new antibody has shown potential as treatment for HIV with a mid-stage trial showing it suppressed the Share XAntibody suppresses HIV for four monthshttps://pharmaphorum.com/news/antibody-suppresses-hiv-for-four-months/
AI firm Insitro signs Gilead as first pharma partner with NASH dealLess than a year after coming out of stealth mode with a $65 million first-round last year, artificial Share XAI firm Insitro signs Gilead as first pharma partner with NASH dealhttps://pharmaphorum.com/digital/ai-insitro-gilead-pharma-partner/
Drugs could mimic gut bacteria benefits to treat diabetesIt may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat Share XDrugs could mimic gut bacteria benefits to treat diabeteshttps://pharmaphorum.com/news/drugs-gut-bacteria-diabetes/
Alnylam to file gene-silencing porphyria drugAlnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying Share XAlnylam to file gene-silencing porphyria drughttps://pharmaphorum.com/news/alnylam-to-file-gene-silencing-porphyria-drug/
J&J’s Invokana reduces risk of renal failure in high-risk diabetes patientsJohnson & Johnson’s Janssen pharma unit has announced new results showing that its Invokana diabetes medicine is the Share XJ&J’s Invokana reduces risk of renal failure in high-risk diabetes patientshttps://pharmaphorum.com/news/jjs-invokana-reduces-risk-of-renal-failure-in-high-risk-diabetes-patients/
Gilead and Novo Nordisk collaborate for NASH trialGilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) Share XGilead and Novo Nordisk collaborate for NASH trialhttps://pharmaphorum.com/news/gilead-and-novo-nordisk-collaborate-for-nash-trial/
Wave slips behind in Huntington’s disease antisense raceSlower-than-expected recruitment in trials of two of Wave Life Sciences’ experimental therapies of Huntington’s disease will delay results, Share XWave slips behind in Huntington’s disease antisense racehttps://pharmaphorum.com/news/wave-huntingtons-disease-antisense-race/
Janssen announces first data centres for haematology networkJanssen has announced the first two data centres to join its HONEUR (Haematology Outcomes Network in Europe) collaborative Share XJanssen announces first data centres for haematology networkhttps://pharmaphorum.com/news/janssen-announces-first-data-centres-for-haematology-network/
Trial sets up 2020 filing for Poxel’s novel diabetes drugFrench biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 Share XTrial sets up 2020 filing for Poxel’s novel diabetes drughttps://pharmaphorum.com/news/trial-sets-up-2020-filing-for-poxels-novel-diabetes-drug/
